Receptor for Urokinase Is Present in Tumor-associated Macrophages in Ductal Breast Carcinoma

Cancer Research

Volumn 53, Issue 8, 1993, Pages 1911-1915

  Ronne, E ^c   Pyke, C ^a,a   Htfyer Hansen, G ^a   Briinner, N ^a   Dane, K ^a  

^a FINSEN LABORATORY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BINDING SITE; CANCER CYTODIAGNOSIS; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; RECEPTORS, CELL SURFACE; SUPPORT, NON-U.S. GOV'T;

EID: 0027215058     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Reich, E. Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In: R. B. Berlin, H. Herrmann, I. H. Lewpow, and J. M. Tanzer (eds.). Molecular Basis of Biological Degradative Processes, pp. 155-169. New York: Academic Press, 1978.
2. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
3. Saksela, O., and Riflcin, D. B. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol., 4: 93-126, 1988.
4. Murphy, G., Ward, R., Gavrilovic, J., and Atkinson, S. Physiological mechanisms for metalloproteinase activation. In: H. Birkedal-Hansen, Z. Werb, H. Welgus, and H. Van Wart (eds.). Matrix Metalloproteinase and Inhibitors, pp. 224-230. Stuttgart: Gustav Fischer Verlag, 1992.
5. Sato, Y., Tsuboi, R., Lyons, R., Moses, H., and Rifkin, D. B. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J. Cell Biol., III: 757-763, 1990.
6. Vassalli, J-D., Baccino, D., and Belin, D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100: 86-92, 1985.
7. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Associan, R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA, 82: 4939-4943, 1985.
8. Nielsen, L. S., Kellerman, G. M., Behrendt, N., Picone, R., Dano, K., and Blasi, F. A 55,000-60,000 Mf receptor protein for urokinase-type plasminogen activator. Identi-8 G. H0yer-Hansen, personal communication. fication in human tumor cell lines and partial purification. J. Biol. Chem., 263: 2358-2363. 1988.
9. Behrendt, N. Ronne, E., Ploug, M., Petri, T., Lober, D., Nielsen, L. S., Schleuning, W-D., Blasi, F., Appella, E. A., and Dano, K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem., 265: 6453-6460, 1990.
10. Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Dano, K., Appella E., and Blasi, F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J., 9: 467-474, 1990.
11. Borglum, A. D., Byskov, A., Ragno, P., Roldan, A. L., Tripputi, P., Cassani, G., Dano, K., Blasi, F., Bolund, L., and Kruse, T. A. Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q 13.1 -q 13.2. Am. J. Hum. Genet., 50: 492-497, 1992.
12. Ploug, M., Behrendt, N., Lober, D., and Dano, K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin. Thromb. Hemostasis, 17: 183-193, 1991.
13. Petersen, L. C., Lund, L. R., Nielsen, L. S., Dano, K., and Skriver, L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem., 263: 11189-11195, 1988.
14. Blasi, F., Vassalli J-D., and Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801-805, 1987.
15. Ellis, V., and Dano, K. Plasminogen activation by receptorbound urokinase. Semin. Thromb. Hemostasis, 17: 194-200, 1991.
16. Pyke, C., Kris ten sen. P., Ralfkisr, E., Grondahl-Hansen, J., Eriksen, J., Blasi, F., and Dano, K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol., 138: 1059-1067, 1991.
17. Grondahl-Hansen, J., Ralfkisr, E., Kirkeby, L. T., Kristensen, P., Lund, L. R., and Dano, K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol., 138: 111-117, 1991.
18. Hewitt, R. E., Leach, I. H., Powe, D. G., Clark, I. M., Cawston, T. E., and Turner, D. R. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int. J. Cancer, 49: 666-672, 1991.
19. Pyke, C., Ralfkisr, E., Tryggvason, K., and Dano, K. Messenger RNA for two type IV collagenases is located in non-malignant stromal cells in human colon cancer. Am. J. Pathol., 142: 359-365, 1993.
20. Pyke, C., Kristensen, P., Ralfkisr, E., Eriksen, J., and Dano, K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the stroma Cancer Res., 51: 4067-4071, 1991.
21. Ronne, E., Behrendt, N., Ellis, V., Ploug, M., Dano, K., and Hoyer-Hansen, G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett., 288: 233-236, 1991.
22. Kristensen, P., Pyke, C., Lund, L. R., Andreasen, P. A., and Dano, K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry, 93: 559-566, 1990.
23. Shulman, M., Wilde, C. D., and Kohler, G. A better cell line for making hybridomas secreting specific antibodies. Nature (Lond.), 276: 269-270, 1978.
24. Guesdon, J-L., Temynck, T., and Avrameas, S. The use of avidin-biotin interaction in immunoenzymatic techniqeus. J. Histochem. Cytochem., 27: 1131-1139, 1979.
25. Ploug, M., Plesner, T., Ronne, E., Ellis, V., Hoyer-Hansen, G., Hansen, N. E., and Dano, K. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood, 79: 1447-1455, 1992.
26. Hoyer-Hansen, G., Ronne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L. R., Ellis, V., and Dano, K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand binding domain. J. Biol. Chem., 297: 18224-18229, 1992.
27. Mignatti, P., Robbins, E., and Rifkin, D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 487-498, 1986.
28. Ossowski, L., Clunie, G., Masucci, M. T., and Blasi, F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol., 115: 1107-1112, 1991.
29. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107: 2437-2445, 1988.
30. Skriver, L., Larsson, L-I., Kielberg, V., Nielsen, L. S., Andresen, P. B., Kristensen, P., and Dano, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99: 753-758, 1984.
31. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
32. Janicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gossner, W., and Graeff, H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-78, 1990.
33. Kristensen, P., Eriksen, J., and Dano, K. Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J. Histochem. Cytochem., 39: 341-349, 1991.
34. Normann, S. J. Macrophage infiltration and tumor progression. Cancer Metastasis Rev., 4: 277-291, 1985.
35. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco, L. The origin and function of tumor-associated macrophages. Immunol. Today, 13: 265-270, 1992.
36. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon, P. A new member of the metallopro-teinase gene family is specifically expressed in stromal but not in tumor cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
37. Pyke, C., Ralfkisr, E., Huhtala, P., Hurskainen, T., Dano, K., and Tryggvason, K. Localization of messenger RNA for 72-kDa and 92-kDa type IV collagenases in human skin cancers by in situ hybridization. Cancer Res., 52: 1336-1341, 1992.
38. Nykjszr, A., Petersen, C. M., Christensen, E. I., Davidsen, O., and Gliemann, J. Urokinase receptors in human monocytes. Biochim. Biophys. Acta, 1052: 399-407, 1990.
39. Lund, L. R., Romer, J., Ronne, E., Ellis, V., Blasi, F., and Dano, K. Urokinase receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factormi in human A549 lung carcinoma cells. EMBO J., 10: 3399-3407, 1991.
40. Min, H. Y., Semnani, R., Mizukami, I. F., Watt, K., Todd, R. F., and Liu, D. Y. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J. Immunol., 148: 3636-3642, 1992.
41. Yoshida, K., Yokozaki, H., Niimoto, M., Ito, H., and Tahara, E. Expression of TGF-0 and procollagen type I and type III in human gastric carcinomas. Int. J. Cancer, 44: 394-398, 1989.
42. Ohtani, H., Kuroiwa, A., Obinata, M., Ooshima, A., and Nagura, H. Identification of type I collagen-producing cells in human gastrointestinal carcinomas by non-radioactive in situ hybridization and immunoelectron microscopy. J. Histochem. Cytochem., 40: 1139-1146, 1992.
43. Boyd, D., Florent, G., Kim, P., and Brattain, M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res., 48: 3112-3116, 1988.